Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Christine Walsh, M.D., M.S.
Christine Walsh, M.D., M.S.

Specialty:

Gynecologic oncology
Gynecology
Obstetrics and gynecology

General Information:

Gender:
Female
Language(s):
English

Affiliation(s):

Associate Professor in Residence, Department of Obstetrics and Gynecology
Director, Gynecologic Oncology Fellowship Program at UCLA/Cedars-Sinai Medical Center
Core Member, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Member, Women’s Cancer Program, Cedars-Sinai Medical Center
Member, JCCC Community

Hospital Affiliation(s):

Cedars-Sinai Medical Center

Education:

Fellowship:
Gynecologic Oncology, UCLA and Cedars-Sinai Medical Center, 2002 - 2005
Residency:
Obstetrics and Gynecology, Brigham and Women’s Hospital and Massachusetts General Hospital, 1999 - 2002
Internship:
Obstetrics and Gynecology, Brigham and Women’s Hospital and Massachusetts General Hospital, 1998 - 1999
Medical Degree:
M.D., Columbia College of Physicians and Surgeons, 1998
Degree:
Master of Science in Clinical Research, Geffen School of Medicine at UCLA, 2007

Contact Information:

Phone:
(310) 423-5456
Email:
Website:

Practice Information:

Clinical Interest(s):
Cervical cancer
Chemotherapy
Colposcopy
Endometrial cancer
Gynecologic cancers
Laparoscopic surgery
Oncology
Ovarian cancer
Robotic surgery
Uterine cancer
Vaginal cancer
Vulvar cancer

Scientific Interest(s):

Dr. Christine Walsh’s research focuses on ovarian cancer genetics with the goal of identifying novel therapeutic targets and treatments. She studies the role of various DNA repair and cell cycle proteins in ovarian cancer initiation, progression and response to therapy, as well as the relationship between thrombosis and ovarian cancer prognosis. The ultimate goal of this work is to identify molecular targets that can be inhibited to restore platinum sensitivity to chemoresistant ovarian cancer and to improve patient prognosis and survival.

Selected Cancer-Related Publications:

Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013 Dec;131(3):541-5. doi: 10.1016/j.ygyno.2013.09.005. Epub 2013 Sep 14.

Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.

Taylor-Harding B, Agadjanian H, Nassanian H, Kwon S, Guo X, Miller C, Karlan BY, Orsulic S, Walsh CS. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. Br J Cancer. 2012 Jan 17;106(2):333-43. doi: 10.1038/bjc.2011.546. Epub 2011 Dec 13.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806.

Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, Karlan BY. Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res. 2008 Dec 1;14(23):7645-51. doi: 10.1158/1078-0432.CCR-08-1291.